RxDoctor Payments Data

Dolores Stefanski

Psychiatric/Mental Health · New Port Richey, FLNPI 1295070647

Payments from drug & device makers

$4,787in general payments, 2019–2025

Across 204 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • Acadia Pharmaceuticals Inc$1K
  • Neurocrine Biosciences, Inc.$693
  • Alpha Cognition USA, Inc.$296
  • Otsuka America Pharmaceutical, Inc.$291
  • Avanir Pharmaceuticals, Inc.$173
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$4,787100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,787 in reported general payments places this provider in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$96,448
Medicare patients
447
Services billed
1,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine264$1,249,787
NuplazidPimavanserin Tartrate191$978,335
Invega SustennaPaliperidone Palmitate151$474,016
NuedextaDextromethorphan Hbr/Quinidine280$412,401
Austedo XrDeutetrabenazine18$209,345
IngrezzaValbenazine Tosylate11$79,338
SecuadoAsenapine37$54,553
Risperidone ErRisperidone Microspheres26$42,480
Divalproex Sodium288$20,980
CaplytaLumateperone Tosylate24$19,774
Risperidone259$18,507
Ziprasidone Mesylate33$14,279
Haloperidol Decanoate192$13,806
Trazodone Hcl629$11,488
Ziprasidone Hcl73$9,284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$2,182$1,459,132282 claims
Acadia Pharmaceuticals IncNuplazid$1,121$978,335191 claims
Avanir Pharmaceuticals, Inc.Nuedexta$173$412,401280 claims
Neurocrine Biosciences, Inc.Ingrezza$693$79,33811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in New Port Richey

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →